Autonomize AI is a healthcare-native agentic AI company that orchestrates multi-agent workflows to streamline labor-intensive, highly regulated operations across payers, providers, and life sciences organizations. Founded in 2022 by Ganesh Padmanabhan and Kris Nair, the Austin-based company set out to attack the administrative burden that consumes clinical staff time, building AI Copilots that read and reason over unstructured clinical documents to accelerate decisions that have traditionally required manual nurse and physician review.
The platform centers on care management and utilization review, two of the most expensive and clinician-heavy functions inside health plans. Autonomize's AI Copilots automate prior authorizations, benefits verification, and care plan generation, reportedly delivering up to 50 percent faster decisions on prior authorizations and claims while keeping humans in the loop for regulated determinations. The company says its system saves customers roughly 36,000 clinical hours per month and generates over 100,000 automated care plans monthly, metrics aimed at the operational leaders who buy in this category.
Because the workflows touch protected health information and regulated decisions, Autonomize emphasizes a healthcare-native architecture with guardrails, traceability, and human review built in. This positioning matters in a market where AI in prior authorization and claims review is drawing scrutiny from regulators and consumer advocates, and where payers need defensible audit trails for any automation that influences coverage decisions.
Autonomize raised a $28 million Series A in June 2025 led by Valtruis, The Cigna Group Ventures, and Tau Ventures, with participation from existing investors Asset Management Ventures, ATX Venture Partners, and Capital Factory, bringing total funding to roughly $32 million. The strategic participation of a major payer's venture arm signals demand from the buy side of healthcare for tools that compress utilization-management and care-management costs.
The company serves Fortune 100 healthcare enterprises and uses the funding to scale its orchestration platform, expand agent capabilities, and deepen its footprint in payer and life sciences operations, while navigating the regulatory and trust considerations inherent in automating clinical-adjacent decisions.